Note 7 - Goodwill

12 Months Ended

Dec. 28, 2024

Notes to Financial Statements

Goodwill Disclosure [Text Block]

7.    GOODWILL

Goodwill represents the premium paid over the fair value of the net tangible and intangible assets acquired in business combinations.  The Company tests goodwill for impairment on an annual basis as of the last day of the Company's fiscal year or more frequently if events occur or circumstances change indicating that the fair value of goodwill may be below the carrying amount.  The Company reviewed industry and market conditions, reporting unit specific events as well as overall financial performance and determined that no indicators of impairment of goodwill existed in its Engineering and Specialty Health Care segments during the fiscal year ended December 28, 2024 and for all segments during the year ended December 30, 2023.  Since the Company remeasured contingent consideration associated with its Life Sciences, Data and Solutions segment, the Company determined that further testing was necessary. After comparing the fair value of the Life Sciences, Data and Solutions segment to its carrying amount, the Company determined that no impairment loss occurred for the Company’s goodwill during the fiscal years ended December 28, 2024 or December 30, 2023.

The changes in the carrying amount of goodwill for the fiscal years ended December 28, 2024 and December 30, 2023 are as follows:

	Engineering		Specialty Health Care		Life Sciences, Data & Solutions		Total
Balance as of December 31, 2022	$	11,918	$	2,398	$	7,831	$	22,147
No change in fiscal 2023		-		-		-		-
Balance as of December 30, 2023	$	11,918	$	2,398	$	7,831	$	22,147
No change in fiscal 2024		-		-		-		-
Balance as of December 28, 2024	$	11,918	$	2,398	$	7,831	$	22,147